Imagine a temporary waive of intellectual property rights for life- saving vaccines.

What is the economic basis for this suggestion?

How would such a waiver affect the market for vaccines and the output and pricing decisions made by this pharmaceutical company?

Could price discrimination provide an alternative solution?

How would these two alternatives compare in terms of welfare and efficiency?